Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us

Registration           Hotel           Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
Poster Session OT1
Poster Session OT2
Poster Session OT3
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6

Program Schedule   >  Poster Sessions - Poster Session OT2

Poster Session OT2 
  Ongoing Clinical Trials 2: Radiation Therapy
OT2-1-01 A personalized approach to understanding the development of radiation-induced fatigue
Mulay S, Grady J, Dowsett R, Liang B, Kamath J, Tannenbaum S. University of Connecticut Health Center, Farmington, CT.
OT2-1-02 Novel combination of toll-like receptor (TLR)-7 agonist imiquimod and local radiotherapy in the treatment of breast cancer chest wall recurrences or skin metastases
Janosky M, Demaria S, Novik Y, Oratz R, Tiersten A, Goldberg J, Wang E, Marincola F, Fenton-Kerimian M, Maisonet O, Axelrod D, Sacris E, Levine P, Formenti S, Adams S. New York University; National Institute of Health.
OT2-1-03 Preoperative accelerated partial breast irradiation trial (PAPBI); defining radiosensitivity
Elkhuizen PHM, Bartelink H, van de Vijver M, Rutgers E, Loo C, Vogel W, Rivera S, Lekberg T, van den Bongard D. The Netherlands Cancer Institute, Amsterdam, Netherlands; Amsterdam Medical Center, Amsterdam, Netherlands; Institute Gustave Roussy, Villejuif, France; Karolinska Institutet, Stockholm, Sweden; Utrecht University Medical Center, Utrecht, Netherlands.
  Ongoing Clinical Trials 2: Surgery
OT2-2-01 Withdrawn
OT2-2-02 Hypnosis and paravertebral block in breast cancer surgery: A pilot study to evaluate pain management and surgical margin status
Cottrel M, Podeur M, Le Joliff D, Amouroux P, Assael M, Duros L, Dupré P-F, Gueret G, Ozier Y. CHU de Brest, Brest, France.
  Ongoing Clinical Trials 2: DCIS
OT2-3-01 The LORIS trial: A multicentre, randomized phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ
Francis A, Bartlett JMS, Billingham LJ, Bowden SJ, Brookes CL, Dodwell DJ, Evans AZ, Fallowfield LJ, Gaunt CH, Hanby AM, Jenkins VA, Pinder S, Reed MW, Roberts T, Thomas JS, Wallis MG, Wilcox MH, Rea DW. Queen Elizabeth Hospital, Birmingham, United Kingdom; University of Birmingham, Birmingham, United Kingdom; Ontario Institute for Cancer Research, Toronto, ON, Canada; University of Dundee, Dundee, United Kingdom; University of Sussex, Brighton, United Kingdom; University of Leeds, Leeds, United Kingdom; King's College London, London, United Kingdom; University of Sheffield, Sheffield, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Addenbrooke's Hospital, Cambridge, United Kingdom; Independent Cancer Patients' Voice, England, United Kingdom; St. James's Hospital, Leeds, United Kingdom.
OT2-3-02 NSABP B-43: A phase III clinical trial to compare trastuzumab (T) given concurrently with radiation therapy (RT) to RT alone for women with HER2+ DCIS resected by lumpectomy (Lx)
Cobleigh MA, Anderson SJ, Juilan TB, Siziopikou KP, Arthur DW, Rabinovitch RA, Zheng P, Mamounas EP, Wolmark N. National Surgical Adjuvant Breast and Bowel Project (NSABP); Rush University; University of Pittsburgh Graduate School of Public Health; Allegheny Cancer Center at Allegheny General Hospital; Northwestern University Feinberg School of Medicine; Virginia Commonwealth University; University of Colorado Denver; MD Anderson Cancer Center, Orlando.
  Ongoing Clinical Trials 2: Case Management
OT2-4-01 Add-aspirin trial: A phase III double-blind placebo-controlled randomized trial assessing the addition of aspirin after standard primary therapy in breast cancer and other early stage common solid tumours (CRUK/12/033)
Ring A, Langley RE, Cafferty FH, Gupta S, Wilson RH, Kynaston HG, Pramesh C, Murphy C, Parmar MKB, Cameron DA. Brighton and Sussex Medical School, Brighton, United Kingdom; MRC Clinical Trials Unit, London, United Kingdom; Tata Memorial Hospital, Mumbai, India; Queen's University Belfast, Belfast, United Kingdom; Cardiff School of Medicine, Cardiff, United Kingdom; University of Edinburgh, Edinburgh, United Kingdom.
OT2-4-02 Young and strong: A randomized trial to evaluate a program for young women with breast cancer
Partridge AH, Ruddy KJ, Barry WT, Greaney M, Sprunck-Harrild K, Meyer ME, Baker EL, Ligibel J, Emmons KM. Dana-Farber Cancer Institute, Boston, MA; Harvard Medical School, Boston, MA; Harvard School of Public Health, Boston, MA.
  Ongoing Clinical Trials 2: Survivorship
OT2-5-01 The PREDICT study (prospective, randomized early detection and intervention after breast cancer - Treatment, for women at risk of lymphedema)
Taghian AG, Skolny MN, O'Toole J, Miller CL, Jammallo LS, Horick N, Elliott K, Specht MC. Massachusetts General Hospital, Boston, MA.
OT2-5-02 Randomized trial evaluating a coordinated survivorship care program for early stage breast cancer
Ruddy KJ, Baker EL, Guo H, Goldstein MJ, Winer EP, Shulman LN, Partridge AH. Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA.
  Ongoing Clinical Trials 2: Targeted Therapies
OT2-6-01 Phase 2 study of palbociclib (CDK 4/6 inhibitor) for ER positive, HER2- negative post-menopausal advanced breast cancer patients recurring after hormonal therapy (to reverse endocrine resistance - TREnd trial)
Malorni L, Sanna G, Pestrin M, Siclari O, Biganzoli L, Biagioni C, Cappadona S, Migliaccio I, Guarducci C, Boni L, Baldari D, Minisini AM, Curigliano G, Koehler M, Buyse M, Di Leo A. Hospital of Prato, Istituto Toscano Tumori, Prato, Italy; Translational Research Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy; Clinical Trials Coordinating Center, Careggi University Hospital, Istituto Toscano Tumori, Firenze, Italy; University and General Hospital, Udine, Italy; Early Drug Development for Innovative Therapies Division, European Institute of Oncology, Milano, Italy; Pfizer Global Research and Development, Pfizer Inc., San Diego, CA; International Drug Development Institute (IDDI), Louvian-la-Neuve, Belgium; Hasselt University, Hasselt, Belgium.
OT2-6-02 Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): A global, placebo-controlled, randomized, double-blind, phase 3 clinical trial
Goss PE, Barrios CH, Chan A, Finkelstein DM, Iwata H, Martin M, Braun A, Zhou Y, Maniar T, Coleman RE. Cancer Center, Massachusetts General Hospital, Boston, MA; PUCRS School of Medicine, Padre Chagas, Brazil; Breast Clinical Trials Unit, Breast Cancer Research, Perth, Western Australia, Australia; Massachusetts General Hospital, Boston, MA; Aichi Cancer Center, Nagoya, Chikusa-ku, Japan; Hospital Gregorio Maranon, Madrid, Spain; Amgen Inc., Thousand Oaks, CA; Academic Unit of Clinical Oncology, CR-UK/YCR Sheffield Cancer Research Centre, Sheffield, United Kingdom.
OT2-6-03 A single arm, preoperative, pilot study to evaluate the safety and biological effects of orally administered reparixin in early breast cancer patients who are candidates for surgery
Goldstein LJ, Sparano J, Perez RP, Vito C, Reuben JM, Landis MD, McCanna S, Ruffini PA, Cristofanilli M, Chang JC. The Hospital of Fox Chase Cancer Center, Philadelphia, PA; Albert Einstein Cancer Center/Montefiore Medical Center, Bronx, NY; University of Kansas Medical Research Center, Fairway, KS; City of Hope National Medical Center, Duarte, CA; MD Anderson Cancer Center, Houston, TX; The Methodist Hospital Research Institute, Houston, TX; Development, Dompé s.p.a., Milano, Italy; Thomas Jefferson University, Philadelphia, PA.
OT2-6-04 Dovitinib, a receptor tyrosine kinase inhibitor in combination with fulvestrant in postmenopausal endocrine resistant human epidermal growth factor receptor 2 negative (HER2-) / hormone receptor-positive (HR+) breast cancer: A phase II, randomized, double blind, placebo-controlled study
Andre F, Neven P, Musolino A, Latini L, Campone M, Cortes J, Barrios C, Squires M, Zhang Y, Deudon S, Gogov S, Blackwell K. Institut Gustave Roussy, Villejuif, France; Hospital Gasthuisberg, Leuven, Belgium; University Hospital of Parma, Parma, Italy; Ospedale di Macerata, Macerata, Italy; Institut de Cancérologie de l'Ouest-René Gauducheau, Saint-Herblain, France; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Pontifícia Universidade Católica do Rio Grande do Sul School of Medicine, Porto Alegre, Brazil; Novartis Pharma AG, Basel, Switzerland; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Duke University Medical Center, Durham, NC.
OT2-6-05 Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
Kalinsky K, Chi D-C, Lee S, Adelson K, Andreopoulou E, Crew KD, Vahdat L, Sparano JA, Hershman DL, Califano A, Silva J, Maurer MA. Columbia University Medical Center, New York, NY; Mount Sinai Hospital, New York, NY; Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY; Will Cornell Medical College, New York, NY.
OT2-6-06 Pre-surgical "window of opportunity" trial of metformin and atorvastatin in newly diagnosed operable breast cancer
Kalinsky K, Baer L, Tsai WY, Ngan MC, Feldman SM, Taback B, Ananthakrishnan P, Chen-Seetoo M, Hibshoosh H, Crew KD, Maurer MA, Hershman DL. Columbia Universtiy Medical Center, New York, NY.
OT2-6-07 Buparlisib (BKM120), an oral pan-PI3K inhibitor, in combination with paclitaxel in patients with HER2-negative, locally advanced or metastatic breast cancer, with or without PI3K pathway activation: A phase II, randomized, double-blind, placebo-controlled study – BELLE-4
Martin M, Batista N, Shtivelband M, Chan A, Delaloge S, Dirix L, Lee SC, Le Mouhaer S, Nanni S, DiTomaso E, Urban P, O'Shaughnessy J. Hospital General Universitario Gregorio Marañon, Madrid, Spain; Hospital Universitario de Canarias, Tenerife, Spain; Ironwood Cancer and Research Centers, Chandler, AZ; Mount Hospital, Curtin University, Perth, Western Australia, Australia; Institut de Cancerologie Gustave Roussy, Villejuif, France; Sint- Augustinus Hospital, Antwerp, Belgium; National University Cancer Institute, Singapore; Novartis Pharmaceuticals Corporation, Rueil-Malmaison, Paris, France; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Novartis Institutes for BioMedical Research, Inc., Cambridge, MA; Novartis Pharmaceuticals Corporation, Basel, Switzerland; Texas Oncology, Baylor Charles A. Sammons Cancer Center, US Oncology, Dallas, TX.
OT2-6-08 Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer – NeoPHOEBE
Loi S, Loibl S, Di Cosimo S, Nekljudova V, Flamen P, Saini KS, Michiels S, de la Pena L, Nanni S, Urban P, Piccart M, Von Minckwitz G, Baselga J. Peter MacCallum Cancer Centre, East Melbourne, Australia; German Breast Group, Neu-Isenburg, Germany; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Institut Jules Bordet, Brussels, Belgium; Breast International Group, Brussels, Belgium; Institut Gustave Roussy, Villejuif, France; SOLTI Breast Cancer Research Group, Barcelona, Spain; Novartis Pharma AG, Basel, Switzerland; Memorial Sloan-Kettering Cancer Center, New York, NY.
OT2-6-09 4EVER - A phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE)
Tesch H, Fasching PA, Hadji P, Lueftner DI, Janni W, Lux MP, Schneeweiss A, Decker T, Belleville E, Kreuzeder J, Muth M, Wallwiener D. Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt/Main, Germany; University Breast Centre for Franconia, Erlangen, Germany; University Hospital of Giessen and Marburg GmbH, Marburg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University of Ulm, Ulm, Germany; National Center for Tumor Diseases, Heidelberg, Germany; Onkologie Ravensburg, Ravensburg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; University of Tuebingen, Tübingen, Germany.
OT2-6-10 DETECT IV – A multicenter, single arm, phase II study evaluating the efficacy of everolimus in combination with endocrine therapy in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and HER2-negative circulating tumor cells (CTCs)
Schochter F, Melcher C, Hagenbeck C, Friedl TWP, Jäger B, Rack BK, Müller V, Fasching PA, Janni W, Fehm T. University of Ulm, Ulm, Germany; Düsseldorf University Hospital, Düsseldorf, Germany; University Hospital Ludwig-Maximilians-University, Munich, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Erlangen University Hospital, Erlangen, Germany.
OT2-6-11 PENELOPE: Phase III study evaluating palbociclib (PD-0332991), a cyclin-dependent kinase (CDK) 4/6 inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy (GBG-78/BIG1-13)
von Minckwitz G, Bear H, Bonnefoi H, Colleoni M, Gelmon K, Gnant M, Kim S-B, Loibl S, Makris A, Martin M, Nekljudova V, Rugo H, Saini KS, Toi M, Untch M, Werutsky G. German Breast Group, Neu-Isenburg, Germany; Virginia Commonwealth University, Richmond, USA; CRLC Bordeaux - Institut Bergonié, Bordeaux, France; Istituto Europeo di Oncologia, Milano, Italy; BC Cancer Agency, BC, Canada; Medizinische Universität Wien, Austria; University of Ulsan College of Medicine, Seoul, Korea; Mount Vernon Cancer Centre, Northwood, United Kingdom; El Grupo Español de Investigación en Cáncer de Mama, Spain; University of California, San Francisco, USA; Jules Bordet Institute, Brussels, Belgium; University Hospital Kyoto, Japan; Helios Kliniken Berlin, Germany; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; University Frankfurt, Universidade Federal de São Paulo.
OT2-6-12 A randomized pacebo-controlled phase II trial evaluating the effect of hedgehog inhibitor LDE225 on bone marrow disseminated tumor cells in women with early stage estrogen receptor negative and HER2 negative breast cancer
Aft R, Weilbaecher K, Trinkaus K, Watson M, Bernadt C, Crouch E, Dahiya N, Ellis M, Ma C. Washington University, St. Louis, MO.
OT2-6-13 A randomized phase 2 study of the triplet combination of ridaforolimus (RIDA), dalotuzumab (DALO) and exemestane (EX) compared to the ridaforolimus, exemestane doublet in high proliferation, estrogen receptor positive (ER+) advanced breast cancer
Rugo H, Tredan O, Ro J, Morales S, Musolina A, Afonso N, Ferreira M, Park K, Cortes J, Tan A, Blum J, Eaton L, Mauro D, Gause C, Im E, Baselga J. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Centre Leon Berard, Lyon, France; National Cancer Center, Goyang, Korea; H. de Lleida Arnau de Vilanova, Lerida, Spain; Ospedale Maggiore, Parma, Italy; Instituto Português de Oncologia Francisco Gentil, Porto, Portugal; Korea University Medical Center, Seoul, Korea; Vall d'Hebron University Hospital, Barcelona, Spain; The Cancer Institute of New Jersey, New Brunswick, NJ; Baylor Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX; Merck Research Laboratories, North Wales, PA; Memorial Sloan Kettering, New York, NY.
OT2-6-14 Phase 2, single arm study of a steroid-based mouthwash to prevent stomatitis in women with hormone receptor-positive advanced breast cancer treated with everolimus plus exemestane
Rugo HS, Chambers MS, Litton J, Meyer I, Rogerio J, Demars L, Geronimo J, Warsi G, Meiller TF. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; The University of Texas MD Anderson Cancer Center, Houston, TX; Vanderbilt University, Nashville, TN; Novartis Pharmaceuticals Corporation, East Hanover, NJ; University of Maryland Medical System, Baltimore, MD.
OT2-6-15 Efficacy and safety of vintafolide alone and vintafolide plus paclitaxel vs paclitaxel alone in advanced triple negative breast cancer subjects using etarfolatide subject selection
Schmidt EV, Leighton-Swayze AM, Hanson ME, Brown H, Gause CK, El Galta R, Denker AE, Yao S-L. Merck Sharp & Dohme Corp., Whitehouse Station, NJ.
OT2-6-16 A pivotal multicenter, randomized, study evaluating the novel antibody-drug conjugate CDX-011 in patients with metastatic, triple-negative, high GPNMB over-expressing breast cancer
Yardley DA, Melisko ME, Forero A, Telli M, Cruickshank S, Green J, Yellin M, Davis T, Vahdat LT. Sarah Cannon Research Institute, Nashville, TN; University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Alabama, Birmingham, AL; Stanford University School of Medicine, Stanford, CA; Scott Cruickshank & Associates, Inc., Santa Barbara, CA; Celldex Therapeutics, Inc., Needham, MA; Weill Cornell Medical College, New York, NY; Tennessee Oncology, PLLC, Nashville, TN.
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
Copyright © 2014 SABCS. All rights reserved. - Privacy Policy